Compound details
Dihydrofoliamenthin
| Compound ID | CDAMM01633 |
|---|---|
| Common name | Dihydrofoliamenthin | IUPAC name | [5-ethenyl-1-oxo-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,4a,5,6-tetrahydro-3H-pyrano[3,4-c]pyran-3-yl] 8-hydroxy-2,6-dimethyloct-6-enoate |
| Molecular formula | C26H38O12 |
| Retention time | 2.58 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 543.24 | Theoretical mz | 543.243 |
| Error | 5.29 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 7.0668 |
| Inchi key | MLZWMRAJMJNMHR-LCKCCRTJNA-N |
|---|---|
| Smiles | O=C1OC(OC(=O)C(C)CCCC(=CCO)C)CC2C1=COC(OC3OC(CO)C(O)C(O)C3O)C2C=C |
| Superclass | Lipids and lipid-like molecules |
| Class | Fatty Acyls |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P29274 | ADORA2A | Adenosine A2a receptor | T77365 | SwissTargetPrediction |
| P30542 | ADORA1 | Adenosine A1 receptor | T92072 | SwissTargetPrediction |
| P0DMS8 | ADORA3 | Adenosine A3 receptor | T36059 | SwissTargetPrediction |
| P13866 | SLC5A1 | Sodium/glucose cotransporter 1 | T54771 | SwissTargetPrediction |
| Q9BZP6 | CHIA | Acidic mammalian chitinase (by homology) | T51597 | SEA |
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SEA |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SEA |
| O43868 | SLC28A2 | Sodium/nucleoside cotransporter 2 | T94627 | SwissTargetPrediction |
| P31639 | SLC5A2 | Sodium/glucose cotransporter 2 | T30085 | SwissTargetPrediction |
| P17931 | LGALS3 | Galectin-3 | T72038 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T77365 | DI0319 | Orthostatic hypotension | [ICD-11: BA21] | P29274 | ADORA2A |
| T77365 | DI0331 | Parkinsonism | [ICD-11: 8A00] | P29274 | ADORA2A |
| T77365 | DI0359 | Radionuclide imaging | [ICD-11: N.A.] | P29274 | ADORA2A |
| T92072 | DI0319 | Orthostatic hypotension | [ICD-11: BA21] | P30542 | ADORA1 |
| T36059 | DI0351 | Psoriasis | [ICD-11: EA90] | P0DMS8 | ADORA3 |
| T36059 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | P0DMS8 | ADORA3 |
| T54771 | DI0120 | Diabetes mellitus | [ICD-11: 5A10] | P13866 | SLC5A1 |
| T54771 | DI0175 | Heart failure | [ICD-11: BD10-BD1Z] | P13866 | SLC5A1 |
| T54771 | DI0417 | Type 2 diabetes mellitus | [ICD-11: 5A11] | P13866 | SLC5A1 |
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T30085 | DI0120 | Diabetes mellitus | [ICD-11: 5A10] | P31639 | SLC5A2 |
| T30085 | DI0175 | Heart failure | [ICD-11: BD10-BD1Z] | P31639 | SLC5A2 |
| T30085 | DI0417 | Type 2 diabetes mellitus | [ICD-11: 5A11] | P31639 | SLC5A2 |
| T72038 | DI0190 | Hypertension | [ICD-11: BA00-BA04] | P17931 | LGALS3 |
| T72038 | DI0199 | Idiopathic interstitial pneumonitis | [ICD-11: CB03] | P17931 | LGALS3 |
| T72038 | DI0252 | Melanoma | [ICD-11: 2C30] | P17931 | LGALS3 |
| T72038 | DI0302 | Non-alcoholic fatty liver disease | [ICD-11: DB92] | P17931 | LGALS3 |
| T72038 | DI0351 | Psoriasis | [ICD-11: EA90] | P17931 | LGALS3 |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |